The autonomous blood draw robot that cleared US regulatory review last month will not appear at American labs or clinics for some time. Vitestro, the Dutch company behind it, plans a multicenter US clinical trial before commercial availability and says its first deployments will be in Europe, with the United States to follow.
For patients who saw headlines about a machine that finds a vein and draws blood on its own, the practical answer to when they will see one is not soon, and not everywhere. The gap between authorization and availability shapes who encounters this technology first and under what conditions.
